NCT06910098Completed
Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels
Assessment of Impact of Rosuvastatin Doses on Low Density Lipoprotein Levels, Creatinine Phosphokinase Levels and Aspartate Aminotransferase Levels: A Randomized Controlled Trail
Source: ClinicalTrials.gov · Last updated 4 Apr 2025
Brief summary (registry, in English)
Particpants were divided into groups based on doses of rosuvastatin and were assessed and for CPK, LDL and AST levels
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 195 (actual)
- First submitted
- 22 Mar 2025
- Start date
- 1 Dec 2023
- Primary completion date
- 30 Jun 2024
- Lead sponsor
- Central Park Medical College
- NCT number
- NCT06910098
What you commit to
- Study type: Interventional
- Participants enrolled: 195
- From 1 Dec 2023 to the primary completion date, 30 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- hereditary diseases including familial hypercholesterolemia and kidney diseases
Who the study is looking for
- patients who were already on statins
Age in the registry: 30 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Central Park Teaching Hospital Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.